Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9BZ | ISIN: SE0016786040 | Ticker-Symbol: EY7
Frankfurt
04.11.24
15:29 Uhr
3,340 Euro
-0,210
-5,92 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
W5 SOLUTIONS AB Chart 1 Jahr
5-Tage-Chart
W5 SOLUTIONS AB 5-Tage-Chart
GlobeNewswire (Europe)
3 Leser
Artikel bewerten:
(0)

W5 Solutions AB: W5 Solutions interim report January-June 2024

Despite the challenges we have faced in the first half of 2024, we are optimistic about the future. While significant effort will be required to improve our results, we believe there are strong prospects for sustainable growth in line with our ambitious targets.

Significant events during quarter 2, 2024

  • The Annual General Meeting was held on 23 April. The Annual General Meeting resolved in accordance with the submitted proposals, including the re-election of all members of the Board of Directors.

Significant events after the end of the period

  • In July, a 5-year framework agreement was received within the Power business area of SEK 500 million, an initial order of approximately SEK 100 million is planned to be placed in August.

Other important during the period

  • In April 2024, an order of SEK 32 million was received in the Live-fire product area, as well as an option worth SEK 48 million.
  • In April 2024, a framework agreement for target equipment worth SEK 60 million was obtained, also in the Live-fire product area.
  • In June, it was announced that a new business area structure will be established and that new managers will be appointed.
  • In June, it was announced a strategic partnership with French Exail regarding flight simulators.
  • In June, a 7-year framework agreement was received for advanced live-fire training systems for the Latvian Armed Forces, with an initial order of SEK 7 million.
2024 2023 2024 2023 July 23 - June 24 2023
MSEK Apr-June Apr-June Jan-June Jan-June LTM Jan-Dec
Income 99.7 114.3 196.8 186.0 406.1 395.3
EBITDA -0.2 24.7 4.3 36.5 23.7 56.0
EBITDA-margin, % -0.2 21.6 2.2 19.6 5.8 14.2
EBITA -2.7 22.4 -0.7 33.1 13.4 47.1
EBITA-margin, % -2.7 19.6 -0.3 17.8 3.3 11.9
Net profit for the period -11.8 5.9 -22.4 11.5 -34.9 -1.0
Earnings per share, SEK -0.78 0.44 -1.57 0.86 -2.44 -0.01
Cash flow from operating activities -11.4 -4.1 -34.9 21.5 33.1 89.4
Orders received 115 86 190 128 310 248
Order book 221 256 221 256 221 199

APRIL-JUNE 2024

  • Operating income for the quarter amounted to SEK 99.7 (114.3) million, a decrease with 6 %.
  • Profit, EBITA, for the quarter amounted to SEK -2.7 (22.4) million a decrease of SEK 25.1 million.
  • Cash flow from operating activities amounted to SEK -11,4 (-4.1) million.
  • Orders received during the period amounted to SEK 115 (86) million with an order book at the end of the period of SEK 221 (256) million.

JANUARY-JUNE 2024

  • Operating income for the period amounted to SEK 196.8 (186.0) million, an increase with 6 %.
  • Profit, EBITA, for the period amounted to SEK -0.7 (33.1) million a decrease of SEK 33.8 million.
  • Cash flow from operating activities amounted to SEK -34.9 (21.5) million.
  • Orders received during the period amounted to SEK 190 (128) million with an order book at the end of the period of SEK 221 (256) million.

CEO EVELINA HEDSKOG COMMENTS

Anticipated challenges
As we approach the end of the first six months of 2024, it's with mixed feelings. Our
performance has not met expectations, but we can still find reasons to be positive about
the future. The main reason for our weak financial results, both in terms of revenue and
profitability, can be attributed to a decline in order intake in 2023, which is now manifesting
its consequences. While this situation was not entirely unforeseen, it necessitates a careful
and balanced response.

Fortunately, the decline in order intake is not due to losing business, but rather delays
in contract decisions from several significant prospects. When these delays occur
simultaneously across multiple potential deals, it naturally impacts our operations.
Alongside the low turnover, we are also facing profitability challenges for various reasons.

Profitability affected in the short term
In the short term, our profitability has been impacted by the decision to undertake a group
restructuring and to establish three distinct business areas - Integration, Training, and
Power - to lay the foundation for future growth, both organically and through acquisitions.
This restructuring has incurred one-time costs in the second quarter.
We also have several ongoing and recently completed projects where cost increases have
affected profitability, and we are actively working with cost control in these projects with
good hopes of being able to reverse the negative trend.

As mentioned in the first quarter, the occupancy rate has remained too low, leading
to excessively high wage costs. This situation stems from both a poor order intake in
2023 and our deliberate choice to retain our staff and skills. We are confident that a
period of higher occupancy is imminent. This strategy aligns with macro trends in the
defence industry. Currently, the large system houses and ammunition manufacturers
experience immediate increase in business volumes, while smaller companies are
still awaiting a significant upswing. This trend has been confirmed by a recent report
from the Swedish defence industry trade association SOFF.

Positive messages for the second half of the year
Looking ahead to the second half of the year, there are promising developments on
the horizon. We recently secured a significant five-year framework agreement for
generators, with an initial order worth approximately SEK 100 million in August. This
marks a positive turning point, and we anticipate further growth in our order book in
the latter half of the year.

Additionally, our investment in battery manufacturing has already yielded results,
such as a framework agreement with French Thales, reflecting the increasing
demand for European-manufactured batteries in the defence industry. Our enhanced
focus on the export market has also led to positive outcomes, including long-term
agreements for products in the Live Fire segment with customers like the Latvian
Armed Forces and cooperation with French Exail for flight simulators.

In conclusion, despite the challenges we have faced in the first half of 2024, we are
optimistic about the future. While significant effort will be required to improve our
results, we believe there are strong prospects for sustainable growth in line with our
ambitious targets.

The Interim report is available for download at: https://w5solutions.com/investor-relations/

For more information, please contact:

Evelina Hedskog, President & CEO, W5 Solutions
+46 (0) 70 959 76 67
evelina.hedskog[at]w5solutions.com

About W5 Solutions

W5 Solutions is a Nordic defence group that delivers innovative systems and solutions worldwide to defence and government agencies. We develop high-tech solutions in the areas of power supply, mobile systems, integration and training systems. W5 Solutions' support & services team ensures high reliability through the longevity of the systems.

Learn more at www.w5solutions.com.

The company is listed on the Nasdaq First North Growth Market Stockholm. Redeye AB is the company's Certified Advisor.

This information is information that W5 Solutions AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-23 07:00 CEST.

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.